DT-216 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Sep 27, 2022 → Aug 25, 2023
NCT ID
NCT05573698About DT-216 + Placebo
DT-216 + Placebo is a phase 1 stage product being developed by Design Therapeutics for Friedreich Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT05573698. Target conditions include Friedreich Ataxia.
What happened to similar drugs?
0 of 9 similar drugs in Friedreich Ataxia were approved
Approved (0) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05573698 | Phase 1 | Completed |
Competing Products
20 competing products in Friedreich Ataxia